Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Citi
Daiichi Sankyo
Mallinckrodt
Medtronic
Accenture
Express Scripts
Boehringer Ingelheim
Cipla

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMPLANON

« Back to Dashboard

Clinical Trials for Implanon

Trial ID Title Status Sponsor Phase Summary
NCT00620464 A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) Completed Merck Sharp & Dohme Corp. Phase 3 The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON.
NCT00725413 A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 4 The primary purpose of this study is to investigate the contraceptive efficacy, safety and acceptability of Organon's subdermal etonogestrel implant in healthy female volunteers in various countries in order to obtain country-specific data.
NCT00828542 Safety of the Etonogestrel-Releasing Implant During the Puerperium of Healthy Women Completed University of Sao Paulo N/A The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.
NCT00847587 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant Completed University of Utah Phase 4 A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Implanon

Condition Name

Condition Name for Implanon
Intervention Trials
Contraception 10
HIV 3
Postpartum Period 1
Post Partum 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Implanon
Intervention Trials
Hemorrhage 4
Uterine Hemorrhage 3
Menstruation Disturbances 1
Anemia, Sickle Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Implanon

Trials by Country

Trials by Country for Implanon
Location Trials
United States 7
Brazil 5
Uganda 3
Egypt 2
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Implanon
Location Trials
South Carolina 1
Pennsylvania 1
Colorado 1
North Carolina 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Implanon

Clinical Trial Phase

Clinical Trial Phase for Implanon
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Implanon
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 4
Recruiting 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Implanon

Sponsor Name

Sponsor Name for Implanon
Sponsor Trials
University of Pittsburgh 4
Merck Sharp & Dohme Corp. 3
Makerere University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Implanon
Sponsor Trials
Other 31
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Citi
Healthtrust
AstraZeneca
Farmers Insurance
Mallinckrodt
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.